Patients | 76 (80%) | 19 (20%) | |
Respiratory samples per patient n | 8 (5–12) | 7 (4–11) | 0.45 |
Pseudomonas aeruginosa-positive samples per patient | 2 (1–3) | 4 (2–6) | 0.0005 |
Pseudomonas aeruginosa-negative samples per patient | 6 (3–10) | 3 (1–7) | 0.04 |
Pseudomonas aeruginosa presence before LTx | 48 (63%) | 7 (37%) | >0.99 |
Samples per patient | | | 0.006 |
1 | 38 (50%) | 3 (16%) | |
2–4 | 31 (41%) | 10 (53%) | |
5–9 | 7 (9%) | 6 (32%) | |
Type of transplant | | | 0.86 |
SSLTx | 72 (95%) | 18 (95%) | |
SLTX | 3 (4%) | 1 (5%) | |
HLTx | 1 (1%) | 0 (0%) | |
Underlying disease | | | 0.47 |
Emphysema | 30 (39%) | 11 (58%) | |
Cystic fibrosis | 34 (45%) | 5 (26%) | |
Interstitial lung disease | 9 (12%) | 2 (11%) | |
Pulmonary hypertension | 3 (4%) | 1 (5%) | |
Sex male | 41 (54%) | 12 (63%) | 0.47 |
Age at transplantation years | 44 (28–59) | 54 (37–61) | 0.22 |
Outcome (February 2018) | | | <0.0001 |
Alive | 58 (76%) | 4 (21%) | |
Redo LTx | 14 (18%) | 1 (5%) | |
Death | 4 (5%) | 14 (74%) | |
Era of LTx year | 2011 (2008–2013) | 2011 (2001–2014) | 0.58 |
DSA | | | 0.048 |
Positive | 8 (11%) | 5 (26%) | |
Negative | 42 (55%) | 5 (26%) | |
Unknown | 26 (34%) | 9 (47%) | |